Bicocca Open Archive

Logo unimib boa
REDAELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.716
EU - Europa 3.394
AS - Asia 2.977
SA - Sud America 433
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 2
Totale 13.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.566
SG - Singapore 1.229
CN - Cina 803
DE - Germania 732
IT - Italia 584
RU - Federazione Russa 470
SE - Svezia 390
IE - Irlanda 376
HK - Hong Kong 366
BR - Brasile 355
UA - Ucraina 234
VN - Vietnam 230
GB - Regno Unito 200
CA - Canada 115
FR - Francia 96
FI - Finlandia 93
IN - India 87
TR - Turchia 47
PL - Polonia 44
BD - Bangladesh 34
BE - Belgio 34
AR - Argentina 33
ID - Indonesia 33
NL - Olanda 33
ZA - Sudafrica 31
JP - Giappone 28
AT - Austria 27
DK - Danimarca 27
KR - Corea 27
MX - Messico 27
ES - Italia 21
IQ - Iraq 21
EC - Ecuador 11
PK - Pakistan 10
VE - Venezuela 10
CO - Colombia 9
EU - Europa 9
IR - Iran 9
LT - Lituania 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
BG - Bulgaria 6
KE - Kenya 6
MA - Marocco 6
CZ - Repubblica Ceca 5
CL - Cile 4
IL - Israele 4
JO - Giordania 4
NP - Nepal 4
PY - Paraguay 4
TN - Tunisia 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
EG - Egitto 3
PE - Perù 3
RO - Romania 3
TT - Trinidad e Tobago 3
AM - Armenia 2
GE - Georgia 2
KG - Kirghizistan 2
MU - Mauritius 2
MY - Malesia 2
NO - Norvegia 2
PT - Portogallo 2
TH - Thailandia 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TW - Taiwan 1
UY - Uruguay 1
Totale 13.589
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.126
Singapore 732
Ashburn 679
Woodbridge 589
Fairfield 455
Chandler 372
Frankfurt am Main 370
Hong Kong 365
Dublin 364
Houston 312
Wilmington 259
Milan 248
Dearborn 235
Jacksonville 226
Seattle 187
New York 170
Beijing 138
Cambridge 137
Dallas 114
Los Angeles 113
Santa Clara 107
Princeton 101
Shanghai 78
Göttingen 75
Nanjing 73
Ho Chi Minh City 69
Hefei 64
Munich 63
The Dalles 60
Altamura 49
Lawrence 42
Moscow 39
Lachine 37
Hanoi 36
Brussels 34
São Paulo 34
Buffalo 32
Nanchang 29
Chicago 28
Boardman 26
Dong Ket 26
Tokyo 26
Fremont 25
Fürstenwalde 25
Helsinki 25
Jakarta 25
Shenyang 25
Warsaw 25
London 24
San Diego 24
Guangzhou 23
Seoul 22
Turku 22
Tianjin 21
Vienna 20
Council Bluffs 19
Toronto 19
Andover 18
Ottawa 18
Brooklyn 17
Changsha 17
Chennai 17
Johannesburg 17
Salt Lake City 17
San Jose 17
Falls Church 16
Montreal 16
Nuremberg 16
Jiaxing 15
Lodz 15
Denver 14
Düsseldorf 14
Hangzhou 14
Jinan 14
Kocaeli 13
Lissone 13
Rio de Janeiro 13
Rome 13
Romola 13
Hebei 12
Manchester 12
Monza 12
Pune 12
Ankara 11
Atlanta 11
Boston 11
Mumbai 11
Norwalk 11
Pavia 11
Stockholm 11
Da Nang 10
Haiphong 10
Huizen 10
Kent 10
Kunming 10
Orem 10
Poplar 10
San Francisco 10
Edmonton 9
Zhengzhou 9
Totale 9.223
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 514
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 442
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 404
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 359
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 355
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 329
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 322
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 319
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 319
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 314
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 310
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 307
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 305
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 284
Inhibition of RET tyrosine kinase by SU5416 281
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 280
Idiopathic erythrocytosis: a germline disease? 279
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 278
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 278
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 278
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 276
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 271
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 269
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 268
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 262
Dual kinase targeting in leukemia 257
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 255
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 252
Reply to P. Laneuville et al 252
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 249
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 249
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 249
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 238
Expression, purification, and inhibition of human RET tyrosine kinase 235
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 234
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 229
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib 222
BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients 215
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants 215
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 214
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 203
Novel targeted therapeutics for MEN2 202
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 198
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 196
Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein 192
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 186
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBa mediated p53 nuclear exclusion 185
Volatile Sedation for Acute Respiratory Distress Syndrome Patients on Venovenous Extracorporeal Membrane Oxygenation and Ultraprotective Ventilation 185
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 182
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 169
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 154
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 146
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 145
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform InfraRed microspectroscopy and unsupervised Hierarchical Cluster Analysis. 144
Totale 13.955
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.346
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021701 0 0 0 0 0 0 107 126 126 137 103 102
2021/2022755 53 77 83 47 51 70 38 34 37 81 64 120
2022/20231.491 169 461 145 151 93 197 18 81 84 23 33 36
2023/20241.066 28 34 43 60 139 299 217 38 54 23 15 116
2024/20252.250 141 224 153 129 203 72 151 89 194 378 196 320
2025/20263.147 693 283 487 623 747 285 29 0 0 0 0 0
Totale 13.955